Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer

被引：5

作者：

Andre, Thierry

De Braud, Filippo G.

Jimenez-Rodriguez, Begona

Berton, Dominique

Curigliano, Giuseppe

Arkenau, Tobias

Anton Torres, Antonio

Paez, David

Ellard, Susan

Abdeddaim, Cyril

Castanon Alvarez, Eduardo

Aubin, Francine

Duan, Tao

Veneris, Jennifer Taylor

Zografos, Eleftherios

Starling, Naureen

机构：

[1] Sorbonne Univ, St Antoine Hosp, Dept Med Oncol, AP HP, Paris, France

[2] Univ Milan, Dept Med Oncol, Fdn IRCCS Ist Nazl Tumori & Oncol & Hematooncol D, ENETS Ctr Excellence, Milan, Italy

[3] Hosp Clin Univ Virgen Victoria, Malaga, Spain

[4] GINECO & Inst Cancerol Ouest, Ctr Rene Gauducheau, St Herblain, France

[5] European Inst Oncol IRCCS, Div Early Drug Dev Innovat Therapies, IEO, Milan, Italy

[6] Univ Milan, Milan, Italy

[7] Sarah Cannon Res Inst UK Ltd, London, England

[8] Hosp Univ Miguel Servet, Geicam Breast Canc Grp, Zaragoza, Spain

[9] Hosp Santa Creu i St Pau, Barcelona, Spain

[10] BC Canc, Kelowna, BC, Canada

[11] Ctr Lutte Canc Ctr Oscar Lambret, Lille, France

[12] Univ Navarra Clin, Madrid, Spain

[13] Ctr Rech Ctr Hosp Univ Montreal CHUM, Montreal, PQ, Canada

[14] GlaxoSmithKline, Pennington, NJ USA

[15] GlaxoSmithKline, Waltham, MA USA

[16] GlaxoSmithKline, London, England

[17] Royal Marsden NHS Fdn Trust, London, England

[18] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.201

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

201

引用

页数：3